Football Kit Prices Defended as Castore CEO Tom Beahon Says Market Forces Would Lower Prices if Fans Couldn't Afford Them

Immunic CEO Daniel Vitt discussed the company's 2025 highlights and 2026 milestones. Key points include the phase 2 CALLIPER study's 31% reduction in disability worsening in primary progressive MS patients, and consistent long-term results from the EMPhASIS study. Immunic also strengthened its patent position for vidofludimus calcium and reported early findings on IMU-856, which showed increases in natural GLP-1 levels. The company expects top-line data from the phase 3 ENSURE trials by the end of 2026.